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Background-—It is likely that a proportion of poststroke cognitive impairment is sometimes attributable to unidentified prestroke
decline; prestroke cognitive function is also clinically relevant because it is associated with poor functional outcomes, including
death. We investigated the radiological and prognostic associations of preexisting cognitive impairment in patients with ischemic
stroke or transient ischemic attack associated with atrial fibrillation.
Methods and Results-—We included 1102 patients from the prospective multicenter observational CROMIS-2 (Clinical Relevance of
Microbleeds in Stroke 2) atrial fibrillation study. Preexisting cognitive impairmentwas identified using the16-item InformantQuestionnaire
for Cognitive Decline in the Elderly. Functional outcome was measured using the modified Rankin scale. Preexisting cognitive impairment
was common (n=271; 24.6%). The presence of lacunes (odds ratio [OR], 1.50; 95% CI, 1.03–1.05; P=0.034), increasing periventricular
white matter hyperintensity grade (per grade increase, OR, 1.38; 95% CI, 1.17–1.63; P<0.0001), deep white matter hyperintensity grade
(per grade increase, OR, 1.26; 95% CI, 1.05–1.51; P=0.011), and medial temporal atrophy grade (per grade increase, OR, 1.61; 95% CI,
1.34–1.95; P<0.0001) were independently associated with preexisting cognitive impairment. Preexisting cognitive impairment was
associated with poorer functional outcome at 24 months (mRS >2; adjusted OR, 2.43; 95% CI, 1.42–4.20; P=0.001).
Conclusions-—Preexisting cognitive impairment in patients with atrial fibrillation–associated ischemic stroke or transient ischemic
attack is common, and associated with imaging markers of cerebral small vessel disease and neurodegeneration, as well as with
longer-term functional outcome.
Clinical Trial Registration-—URL: http://www.clinicaltrials.gov. Unique identifier: NCT02513316. ( J Am Heart Assoc. 2020;9:
e014537. DOI: 10.1161/JAHA.119.014537.)
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P oststroke dementia is common, affecting up to 41.3% ofpatients in hospital populations.1 Atrial fibrillation (AF) is
increasingly recognized as a key risk factor for dementia, both
in association with and independent of clinically overt ischemic
stroke.2 It is likely that a proportion of poststroke cognitive
impairment is attributable to unidentified prestroke decline.1
The pooled prevalence of prestroke dementia is estimated to be
14.4% (in hospital-based cohorts, on the basis of data from 3
studies); it is associated with both neurodegenerative and
vascular factors1,3 and with poor functional outcome.4–8 Most
data on the clinical and radiological associations of prestroke
cognitive impairment are from small, single-center studies in
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heterogeneous stroke populations, which might not be gener-
alizable to AF-related stroke populations.9–19 Most imaging
studies have focused on global and regional atrophy measures
and white matter changes, with limited descriptions of other
important structural markers of small vessel disease (such as
magnetic resonance imaging [MRI]-visible perivascular spaces
and cerebral microbleeds).
We investigated the prevalence and associations of
preexisting cognitive impairment in patients with ischemic
stroke or transient ischemic attack (TIA) associated with AF.
We hypothesized that patients with preexisting cognitive
impairment would (1) have more evidence of small vessel
disease and neurodegeneration that those without and (2)
show associations with poorer functional outcome at
24 months.
Methods
Data Availability
Analyses for the CROMIS-2 (Clinical Relevance of Microbleeds
in Stroke 2) study are ongoing; once all of these analyses are
completed, the CROMIS-2 Steering Committee will consider
applications from other researchers for access to anonymized
source data.
Patient Selection
This is a predefined substudy nested within CROMIS-2 AF, a
multicenter prospective observational study of patients with
AF-related cardioembolic stroke or TIA, as described previ-
ously.20,21 Briefly, this was a study of adults (aged ≥18 years)
presenting with ischemic stroke or TIA with nonvalvular AF
(confirmed by electrocardiography), who were eligible to start
anticoagulation following their ischemic event.20,21 Patients
who could not have an MRI scan, had contraindications to
anticoagulation, or had previously received therapeutic anti-
coagulation, were excluded.20,21 The study was approved by
the National Research Ethics Service (IRAS reference 10/
H0716/61). Written informed consent was obtained in all
cases.
Informant Questionnaire for Cognitive Decline in
the Elderly
Preexisting cognitive impairment was identified using the 16-
item Informant Questionnaire for Cognitive Decline in the
Elderly (IQCODE). The informant (defined as the patient’s
caregiver, family member, or friend) was asked to compare
the patient’s cognitive and functional performance from
10 years before their stroke or TIA with their performance
just before their stroke or TIA. The 16-item IQCODE includes
16 questions, each of which can be scored between 1 and 5;
the total is then divided by 16 to provide the final score
(range, 1.0–5.0). Preexisting cognitive impairment was
defined as an IQCODE score >3.3; this threshold was based
on data from a systematic review evaluating the diagnostic
accuracy of the IQCODE for detecting clinically diagnosed
dementia (of any cause) in secondary care environments.22
Preexisting cognitive impairment was defined as an IQCODE
score >3.3.22 All patients with a baseline IQCODE were
included in this analysis.
Imaging
Imaging was performed acutely after the index ischemic event
and completed locally at each study center in accordance with
a standardized protocol, which has been published previ-
ously.20 Imaging was performed acutely after the index
ischemic event and completed locally at each study center in
accordance with a standardized protocol including axial T2,
T2* gradient echo sequence, diffusion-weighted imaging,
coronal T1, and fluid-attenuated inversion recovery (FLAIR)
images.20 Sequence parameters were specified for T2*
Clinical Perspective
What Is New?
• We reviewed data from over 1000 patients presenting with
ischemic stroke or transient ischemic attack associated
with atrial fibrillation, recruited as part of the prospective,
multicenter observational CROMIS-2 (Clinical Relevance of
Microbleeds in Stroke 2) atrial fibrillation study.
• We found that preexisting cognitive impairment is common
in patients presenting with atrial fibrillation–associated
ischemic stroke or transient ischemic attack, affecting
nearly a quarter of patients (24.6%).
• Preexisting cognitive impairment was associated with
magnetic resonance imaging markers of cerebral small
vessel disease (lacunes, white matter hyperintensities) and
neurodegeneration (medial temporal atrophy), and was also
associated with poorer functional outcome at 24 months,
independent of the acute ischemic event.
What Are the Clinical Implications?
• Preexisting cognitive impairment might be underrecognized
in patients presenting with ischemic stroke or transient
ischemic attack associated with atrial fibrillation.
• It is important to identify preexisting cognitive impairment in
these patients, as it appears to have prognostic implications.
• We used an informant questionnaire (the Informant Question-
naire for Cognitive Decline in the Elderly) to identify preexisting
cognitive impairment, which might be a useful and relevant tool
in acute stroke; further data validation of this tool is needed.
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gradient echo sequence20; the remaining sequences were
obtained according to local protocols.
All structural markers of cerebral small vessel disease were
rated in accordance with consensus criteria,23 each measure
was rated by a single individual blinded to all clinical
information. Where possible, the hemisphere contralateral to
the acute stroke was preferentially counted.
Previous cortical infarcts were identified using T2 and
FLAIR sequences and confirmed as nonacute through
comparison with diffusion-weighted images. Lacunes were
identified and counted on T2 and FLAIR sequences using
definitions from the Standards for Reporting and Imaging
of Small Vessel Disease criteria.23 White matter hyperin-
tensities (WMHs) in deep and periventricular distributions
were rated on T2 and FLAIR sequences using the Fazekas
scale.24 MRI-visible perivascular spaces in the basal
ganglia and centrum semiovale were rated on T2 and
FLAIR sequences using a previously described validated
visual rating scale.25 Medial temporal atrophy (MTA) was
rated on T1 or FLAIR coronal images using the Scheltens
visual scale.26 Global cortical atrophy (GCA) was rated
with the Pasquier scale using axial T1, FLAIR, or inverted
T2 images.27 Cortical superficial siderosis was identified
on T2* gradient echo sequences and classified as either
focal, involving ≤3 sulci, or disseminated, involving ≥4
sulci.28 Cerebral microbleeds were rated using T2*
gradient echo sequences using the Microbleed Anatomical
Rating Scale.29
Functional Outcomes Following the Index
Ischemic Event
Functional outcome at 24 months was quantified using the
modified Rankin scale (mRS) using multiple ascertainment
methods to maximize follow-up; these included postal ques-
tionnaires sent to patients and their general practitioners, and
death notifications from NHS Digital (previously the Health
and Social Care Information Centre).20 The mRS was
dichotomized, with a score of ≤2 indicating independence.30
Statistical Analysis
We investigated for selection bias by comparing characteris-
tics of those with and without a baseline IQCODE. We then
compared baseline clinical, demographic, and imaging find-
ings in patients with and without preexisting cognitive
impairment. For all continuous variables, data were reviewed
for normality, and if normally distributed, the independent t
test was used. If variables were ordinal or not normally
distributed, the nonparametric Mann–Whitney U test was
used. Chi-squared or Fisher’s exact tests were used for
categorical variables.
The results of univariable comparisons were used to
identify variables for inclusion in multivariable logistic regres-
sion models; variables with P<0.20 were included in the
adjusted analyses, except for situations where variables both
described the same phenomenon (eg, clinical history of
previous ischemic events and imaging evidence of a previous
cortical infarct). The presence of ≥1 acute diffusion-weighted
image lesions was included as a variable in all adjusted
analyses for outcome, to control for the index event (ie, stroke
or TIA). We adjusted for National Institutes of Health Stroke
Scale (a clinical measure of stroke severity) and the presence
of acute diffusion-weighted image changes as measures of
the acute cerebral ischemic event; we did not additionally
adjust for immediate postevent mRS for reasons of collinear-
ity. We instead adjusted for preevent mRS to capture baseline
function. Each model considered only a single neuroimaging
marker at a time.
Post hoc analyses were performed after excluding those
with a preexisting clinical diagnosis of dementia or cognitive
impairment, previous ischemic events, or intracerebral
hemorrhage at study entry. This was to establish whether
any findings in the cohort as a whole were driven by patients
with these diagnoses, which are associated with cognitive
impairment.
Statistical analyses were performed (GB) using Stata
(Version 15).
Results
Of the total number of patients included in the CROMIS-2 AF
study (n=1490), we included 1102 patients for whom a
baseline IQCODE was available; 388 patients were excluded
as baseline IQCODE data were not available. The included
patients were less likely to be current smokers (9.8% versus
16.9%; P<0.0001), more likely to have a formal diagnosis of
dementia or cognitive impairment (2.8% versus 1.6%;
P=0.166), less likely to have had a previous intracerebral
hemorrhage (0.4% versus 1.1%; P=0.116), and more likely to
be taking an antiplatelet drug at study entry (53.7% versus
48.7%; P=0.094). The included patients also had a slightly
higher educational age (mean, 16.4 versus 16.9 years;
P=0.027).
Baseline characteristics for our cohort are shown in
Table 1. In our cohort (n=1102), the mean age was
76.0 years (SD, 10.1), and 471 patients (42.7%) were women.
Preexisting Cognitive Impairment and
Associations
In our cohort, the mean IQCODE score was 3.2 (SD, 0.6; score
range, 1.0–5.0), and 271 (24.6%) patients had IQCODE-
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defined preexisting cognitive impairment, of whom 23 (8.5%)
had a known diagnosis of dementia or cognitive impairment at
study entry. When comparing baseline clinical and demo-
graphic characteristics (Table 1), those with IQCODE-defined
preexisting cognitive impairment were older (79.2 years
versus 75.4 years), more likely to be female (49.1% versus
40.7%), and have a diagnosis of hypertension (70.0% versus
60.6%), diabetes mellitus (20.7% versus 15.7%), heart failure
(6.6% versus 3.6%), prior AF (37.7% versus 31.0%), and
previous ischemic events (27.1% versus 16.5%). They were
more likely to be taking an antiplatelet before their index
event (62.1% versus 51.0%), and had a lower educational age
(mean, 15.7 versus 16.6 years).
The neuroimaging features are presented in Table 2.
Those with preexisting cognitive impairment were more
likely to have previous cortical infarcts and lacunes. They
had higher grades of periventricular WMHs, deep WMHs,
MRI-visible perivascular spaces in the basal ganglia, MTA,
and global cortical atrophy and were more likely to have
multiple cerebral microbleeds. In multivariable logistic
regression analysis (Table 3), in which each imaging
predictor was considered separately, the presence of
lacunes (OR, 1.50, 95% CI, 1.03–1.05), increasing periven-
tricular WMHs (per grade increase, OR, 1.38; 95% CI, 1.17–
1.63), deep WMHs (per grade increase, OR, 1.26; 95% CI,
1.05–1.51) and MTA (per grade increase, OR, 1.61; 95% CI,
1.34–1.95) grade were independently associated with
preexisting cognitive impairment.
Functional Outcome Data
Outcome data at 24 months were available for 922 patients
(83.7%) of whom 480 (52.1%) were functionally dependent
(mRS >2). Preexisting cognitive impairment was associated
with functional dependence at 24 months (n=157, 72.0%
versus n=323, 45.9%) in univariable (unadjusted OR, 3.03;
95% CI, 2.18–4.23; P<0.0001), and multivariable analyses
(OR, 2.43; 95% CI, 1.42–4.20; P=0.001), adjusted for age at
event, sex, hypertension, hypercholesterolemia, diabetes
mellitus, smoking, heart failure, clinical history of previous
ischemic events, educational age, admission National Insti-
tutes of Health Stroke Scale, antiplatelet use, preevent mRS,
and the presence of an acute diffusion-weighted image lesion
at study entry.
Subgroup Analyses
We then repeated these analyses after excluding patients with
a known clinical history of dementia, cognitive impairment,
previous ischemic events, or intracerebral hemorrhage at
study entry, to review whether the associations observed in
the whole cohort were being driven by patients with these
diagnoses (Tables S1 through S4). The results of univariable
and multivariable associations with preexisting IQCODE were
consistent with our main findings, except that the association
with lacunes and preexisting cognitive impairment did not
reach statistical significance in adjusted analyses.
Discussion
In our large, multicentre prospective cohort of patient with AF-
associated ischemic stroke and TIA, we found that nearly a
quarter of patients (24.6%) met IQCODE criteria for preexist-
ing cognitive impairment; this was associated with the
presence of lacunes, periventricular and deep WMHs, and
medial temporal atrophy, but not with other structural
markers of small vessel disease (MRI-visible perivascular
spaces, cortical superficial siderosis, or cerebral microbleeds).
We also found that IQCODE-defined cognitive impairment was
associated with poorer functional outcome at 24 months.
Our findings in an AF-associated cohort are in keeping with
previous studies that have shown that preexisting cognitive
impairment is associated with both neurodegenerative and
vascular factors.9–18,31 AF is increasingly recognized as a key
risk factor for dementia, both in association with and
independent of clinically overt ischemic stroke.32–37 Multiple
mechanisms for this association have been proposed, includ-
ing silent brain infarcts from recurrent embolization, cerebral
hypoperfusion, chronic inflammation, and endothelial dysfunc-
tion or progression of preexisting cerebrovascular or neurode-
generative processes.38–51 We found rates of preexisting
cognitive impairment that were higher than many unselected
stroke populations, and our rates of impairment were also
higher than those reported in other AF cohorts.1,9–18,31 This
might reflect the variability in methods used to diagnose
preexisting cognitive impairment, including different IQCODE
thresholds.
Our finding that MTA is a common and prevalent finding in
patients before stroke provides further evidence that this
neuroimaging feature is important in AF-related ischemic
stroke and TIA. AF has been shown to be associated with
lower hippocampal volumes and poorer memory and learning
performance in stroke-free individuals, and patients with AF
have greater atrophy of their entorhinal cortex and medial
temporal lobes, compared with those without.50,52 The
relationship between AF and global atrophy measures is less
clear; while one study found that AF was associated lower
brain volumes globally, others did not identify an association,
although this might reflect the younger age of these latter
cohorts.50,51,53 An association with MTA but not global
cortical atrophy is in keeping with our results and implicates
Alzheimer disease pathology in the cognitive impairment
associated with AF, a proposal for which there is supporting
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longitudinal and pathological data.2,54–58 Proposed mecha-
nisms by which AF might contribute to Alzheimer disease
pathology include b- and c-secretase inhibition, perivascular
amyloid clearance failures and tau phosphorylation, all of
which might be induced by AF-related cerebral hypoperfu-
sion.2 However, MTA can also be a feature of vascular
pathology, and it might be that this is the dominant pathology
in AF.59,60
We also found an association between WMH severity and
preexisting cognition. Although WMHs in patients with AF
might simply be attributable to age or a shared vascular risk
factor profile,61 there is evidence to suggest that there is an
independent association.62 While WMHs are associated with
poorer cognitive performance,63 the data relating to cognitive
impairment in AF and WMHs is conflicting, with some studies
showing no association.50,51 We did not find an independent
statistically significant association with imaging evidence of
previous cortical infarcts, which might provide further evi-
dence that embolism to the brain (either clinically overt or
“silent”) is not the only mechanism contributing to cognitive
impairment in these patients. The lack of association between
preexisting cognitive impairment and other structural small
vessel disease markers (MRI-visible perivascular spaces and
cerebral microbleeds) is in keeping with data from other
populations, which show inconsistent associations between
cognitive impairment and these markers.64 The presence of
both neurodegenerative and vascular pathologies support the
argument that, in patients with ischemic stroke, preexisting
dementia is a manifestation of “brain aging”3 rather than
attributable to one single pathological process; this is in
contrast with cognitive impairment before spontaneous
intracerebral hemorrhage, where cerebral small vessel dis-
eases (in particular, cerebral amyloid angiopathy) are impor-
tant.19,65 This suggests that any future therapeutic strategies
for cognitive impairment will need to be implemented early
and before stroke to be effective.
We show that cognitive impairment before an ischemic
event is important, as it influences subsequent functional
outcome, independent of the acute ischemic event. This is in
keeping with previous work from other centers, which has
shown associations between prestroke dementia and poor
functional outcomes.4–8 Appropriately identifying preexisting
cognitive impairment can be important for decision making
with regard to postevent rehabilitation.66 Questions remain
about how best to diagnose preexisting cognitive impairment.
The IQCODE has been used extensively67; our data provide
more evidence that the IQCODE might be a useful and
relevant tool in acute stroke, as in our cohort it identifies
patients at risk of subsequent cognitive impairment and
poorer functional outcomes. While it might seem counterin-
tuitive to not assess the patient directly, this is often useful in
stroke where patients are unable to engage in formal testing,
for example, because of aphasia or reduced consciousness.
IQCODE-based estimates of cognition might prove more
Table 1. Baseline Demographic and Clinical Characteristics
All
Preexisting Cognitive Impairment
P ValueAbsent Present
n (%) 1102 831 (75.4) 271 (24.6) 
Age at event, y, mean (SD) 76.0 (10.1) 74.9 (10.1) 79.2 (9.4) <0.00001
Sex, female, n (%) 471 (42.7) 338 (40.7) 133 (49.1) 0.015
Hypertension, n (%) 684 (62.8) 499 (60.6) 185 (70.0) 0.009
Hypercholesterolemia, n (%) 496 (45.6) 370 (45.1) 126 (47.2) 0.555
Diabetes mellitus, n (%) 186 (16.9) 130 (15.7) 56 (20.7) 0.057
Smoking at study entry, n (%) 106 (9.8) 86 (10.5) 20 (7.6) 0.168
Heart failure, n (%) 48 (4.4) 30 (3.6) 18 (6.6) 0.034
Known AF, n (%) 356 (32.6) 255 (31.0) 101 (37.7) 0.042
Previous ischemic event, n (%) 205 (19.1) 134 (16.5) 71 (27.1) <0.0001
Previous intracerebral hemorrhage, n (%) 4 (0.4) 2 (0.2) 2 (0.8) 0.254
Educational age, y, mean (SD) 16.4 (3.5) 16.6 (3.8) 15.7 (2.4) 0.0003
Admission NIHSS, median (IQR) 5 (2–10) 5 (2–10) 4.5 (2–9) 0.9185
Antiplatelet use, n (%) 575 (53.7) 413 (51.0) 162 (62.1) 0.002
Percentage values were calculated using the total number of patients for whom data were available as the denominator. P values are from independent t tests (age at event, educational
age), Mann–Whitney U test (NIHSS), Fisher’s exact test (previous intracerebral haemorrhage), or chi-squared tests (remainder). AF indicates atrial fibrillation; IQR, interquartile range;
NIHSS, National Institutes of Health Stroke Scale.
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Table 2. Comparison of Imaging Features Between Those With and Without Preexisting Cognitive Impairment
All
Preexisting Cognitive Impairment
P ValueAbsent Present
n (%) 1102 831 (75.4) 271 (24.6) 
Imaging evidence of previous cortical infarct, n (%) 207 (18.8) 142 (17.1) 65 (24.1) 0.011
Lacunes, presence, n (%) 188 (17.3) 130 (15.8) 58 (22.1) 0.020
pvWMH grade, n (%)
0 645 (58.5) 527 (63.4) 118 (43.5) <0.00001
1 206 (18.7) 149 (17.9) 57 (21.0)
2 195 (17.7) 125 (15.0) 70 (25.8)
3 56 (5.1) 30 (3.6) 26 (9.6)
dWMH grade, n (%)
0 472 (42.8) 385 (46.3) 87 (32.1) <0.00001
1 431 (39.1) 315 (37.9) 116 (42.8)
2 129 (11.7) 94 (11.3) 35 (12.9)
3 70 (6.4) 37 (4.5) 33 (12.2)
CSO-PVS grade, n (%)
0 58 (5.4) 44 (5.4) 14 (5.4) 0.5043
1 486 (45.2) 361 (44.3) 125 (48.1)
2 324 (30.1) 255 (31.3) 69 (26.5)
3 174 (16.2) 128 (15.7) 46 (17.7)
4 33 (3.1) 27 (3.3) 6 (2.3)
BG-PVS grade, n (%)
0 70 (6.4) 54 (6.6) 16 (6.0) 0.0033
1 782 (71.6) 607 (73.7) 175 (65.3)
2 183 (16.8) 130 (15.8) 53 (19.8)
3 52 (4.8) 30 (3.6) 22 (8.2)
4 5 (0.5) 3 (0.4) 2 (0.8)
MTA grade, n (%)
0 222 (22.0) 192 (24.9) 30 (12.6) <0.00001
1 470 (46.5) 373 (48.4) 97 (40.6)
2 229 (22.7) 161 (20.9) 68 (28.5)
3 66 (6.5) 38 (4.9) 28 (11.7)
4 23 (2.3) 7 (0.9) 16 (6.7)
GCA grade, n (%)
0 355 (32.6) 282 (34.3) 73 (27.3) 0.0078
1 469 (43.1) 354 (43.1) 115 (43.1)
2 246 (22.6) 174 (21.2) 72 (27.0)
3 19 (1.7) 12 (1.5) 7 (2.6)
cSS, presence, n (%) 3 (0.3) 1 (0.1) 2 (0.7) 0.151
CMB, presence, n (%) 230 (20.9) 165 (19.9) 65 (24.0) 0.146
Presence of >1 CMB, n (%) 111 (10.1) 71 (8.5) 40 (14.8) 0.003
Percentage values were calculated using the total number of patients for whom data were available as the denominator. P values are from Mann–Whitney U tests (pvWMH, dWMH, CSO-
PVS, BG-PVS, MTA, and GCA grades), Fisher’s exact test (cSS), or chi-squared tests (remainder). BG-PVS indicates magnetic resonance imaging–visible perivascular spaces in the basal
ganglia; CMB, cerebral microbleed; CSO, magnetic resonance imaging–visible perivascular spaces in the centrum semiovale; cSS, cortical superficial siderosis; dWMH, deep white matter
hyperintensities; GCA, global cortical atrophy; MTA, medial temporal atrophy; pvWMH, periventricular white matter hyperintensities.
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accurate than the potential overestimation resulting from
acute patient testing (which can be influenced by intercurrent
illness) and potential underestimation from formal dementia
diagnoses. The association of IQCODE-defined cognitive
impairment with recognized neurodegenerative and vascular
neuroimaging markers suggests that this is indeed reflective
of significant underlying pathology.
Strengths and Limitations
The strengths of this study include its large size and
multicenter design. We considered a wide range of structural
markers associated with cerebral small vessel disease and
neurodegeneration. However, there are also some limitations.
Patients without IQCODE data (and therefore excluded from
our analysis) were more likely to have a formal diagnosis of
dementia or cognitive impairment, suggesting some selection
bias in our cohort. While the study imaging protocol required
standardized sequences, there was still variability in how
these sequences were obtained, as well as the MRI machines
used by each center, and this could influence our imaging
rating. This is particularly the case for cerebral microbleeds,
where detection may have been influenced by magnetic
resonance field strength; unfortunately, we did not have data
on this. The mean age of our cohort is 76.0 years, and so
these findings may not be generalizable to patients who have
stroke at significantly younger ages; many of the brain
pathologies that coexist and contribute to cognitive impair-
ment are age related. We are unable to provide further data on
whether patients had paroxysmal or persistent AF; there is
some evidence that the former might have particular
relevance for cognition in this context.2,58,68 We do not have
follow-up data on cardiac function for this cohort, and we
acknowledge that this might have influenced functional
outcome. Additionally, the CROMIS-2 AF study included only
patients with recent cardioembolic ischemic stroke or TIA who
were eligible for anticoagulation and able to undergo MRI
scanning; this may not be representative of other patient
groups. As we discussed above, MTA is not specific to
Alzheimer disease; we do not have data on other markers of
Alzheimer disease pathology (measures of Ab and tau, eg,
using positron emission tomography or cerebrospinal fluid)
and therefore cannot comment further on the extent to which
pathologies associated with Alzheimer disease contribute to
our findings. We also acknowledge that the IQCODE threshold
used might not be equivalent to dementia and that a range of
thresholds have been used in the past; the IQCODE has not
been validated for prestroke impairment against a formal
diagnosis of dementia, and we were unable to comment on
this in our study. Formal neuropsychological testing of
multiple domains would provide a more comprehensive
assessment of cognition. Despite this, we would argue that
cognitive impairment at the level identified by the IQCODE is
still of relevance given that it is able to predict future
outcomes in our cohort, although further validation is needed
before the IQCODE can be used for this purpose in clinical
practice.
Summary
In this comprehensive imaging description of the factors
associated with preexisting cognitive impairment in
Table 3. Multivariable Logistic Regression for Imaging Predictors of Preexisting Cognitive Impairment
OR 95% CI P Value
Imaging evidence of previous cortical infarct, presence* 1.23 0.84–1.78 0.288
Lacunes, presence* 1.50 1.03–1.05 0.034
pvWMH, per grade increase 1.38 1.17–1.63 <0.0001
dWMH, per grade increase 1.26 1.05–1.51 0.011
BG-PVS, per grade increase 1.16 0.92–1.47 0.212
MTA, per grade increase 1.61 1.34–1.95 <0.0001
GCA, per grade increase 1.06 0.86 to1.31 0.588
cSS, presence 8.21 0.72–94.5 0.091
CMB, presence 1.10 0.76–1.58 0.620
Presence of >1 CMB 1.49 0.93–2.38 0.093
Each model considered only a single neuroimaging marker at a time. BG-PVS indicates MRI-visible perivascular spaces in the basal ganglia; CMB, cerebral microbleed; cSS, cortical
superficial siderosis; dWMH, deep white matter hyperintensities; GCA, global cortical atrophy; MTA, medial temporal atrophy; OR, odds ratio; pvWMH, periventricular white matter
hyperintensities.
*Adjusted for age at event, sex, hypertension, diabetes mellitus, smoking, heart failure, known atrial fibrillation, educational age, and anti-platelet use. Remaining models were adjusted for
age, sex, hypertension, diabetes mellitus, smoking, heart failure, clinical history of previous ischemic events, known atrial fibrillation, educational age, and antiplatelet use.
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cardioembolic stroke and TIA, we report that preexisting
cognitive impairment is common and associated with imaging
markers of cerebral small vessel disease and neurodegener-
ation, as well as poorer functional outcomes at 24 months.
We also provide evidence that the IQCODE might be useful as
an acute tool in ischemic stroke and TIA, as it appears to
identify those likely to have worse clinical outcomes. Future
work validating the IQCODE in this context (including
establishing the optimal threshold for these patients),
together with further investigation of the factors that
contribute to brain resilience and whether this can be
influenced after ischemic injury, is needed.
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Table S1. Baseline demographic and clinical characteristics. 
 
 All 
Pre-existing cognitive 
impairment p value 
Absent Present 
n (%) 872 689 (79.0) 183 (21.0) - 
Age at event, years , mean (SD) 75.1 (10.2) 74.2 (10.2) 78.5 (9.7) <0.00001 
Sex, female, n (%) 368 (42.2) 280 (40.6) 88 (40.1) 0.070 
Hypertension, n (%) 519 (60.1) 400 (58.6) 119 (66.1) 0.066 
Hypercholesterolaemia, n (%) 361 (41.9) 286 (42.0) 75 (41.7) 0.936 
Diabetes mellitus, n (%) 137 (15.8) 102 (14.9) 35 (19.1) 0.158 
Smoking at study entry, n (%) 91 (10.6) 75 (11.0) 16 (8.9) 0.406 
Heart failure, n (%) 33 (3.8) 21 (3.1) 12 (6.6) 0.027 
Known AF, n (%) 271 (31.4) 206 (30.2) 65 (35.9) 0.138 
Educational age, years, mean 
(SD) 
16.5 (3.7) 46.7 (3.2) 15.7 (2.4) 0.0031 
Admission NIHSS, median 
(IQR) 
5 (2 to 10) 5 (2 to 10) 5 (2 to 10) 0.9840 
Anti-platelet use, n (%) 395 (46.8) 300 (44.9) 95 (53.7) 0.038 
 
Comparison of baseline demographic and imaging characteristics between those with and 
without cognitive impairment prior to their qualifying event. Percentage values were calculated 
using the total number of patients for whom data was available as the denominator. p values 
are from independent t-tests (age, educational age), Mann-Whitney U test (NIHSS), Fisher’s 
exact test (previous intracerebral haemorrhage) or chi-squared tests (remainder).  AF, atrial 
fibrillation; IQR, interquartile range; NIHSS, National Institutes of Health Stroke Scale; SD, 
standard deviation. 
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Table S2. Comparison of imaging features between those and without pre-existing 
cognitive impairment. 
 
 All 
Pre-existing cognitive 
impairment p value 
Absent Present 
n (%) 872 689 (79.0) 183 (21.0) - 
     
Imaging evidence of previous 
cortical infarct, n (%) 
130 (14.9) 93 (13.5) 37 (20.3) 0.021 
Lacunes, presence, n (%) 132 (15.4) 97 (4.2) 35 (19.7) 0.073 
     
pvWMH grade, n 
(%) 
0 531 (60.9) 446 (64.7) 85 (46.5) 
<0.00001 
1 166 (19.0) 124 (18.0) 42 (23.0) 
2 141 (16.2) 97 (14.1) 44 (24.0) 
3 34 (3.9) 22 (3.2) 12 (6.6) 
dWMH grade, n (%) 
0 396 (45.4) 337 (48.9) 59 (32.2) 
<0.00001 
1 337 (38.7) 253 (36.7) 84 (45.9) 
2 95 (10.9) 72 (10.5) 23 (12.6) 
3 44 (5.1) 27 (3.9) 17 (9.3) 
CSO-PVS grade, n 
(%) 
0 50 (5.9) 38 (5.6) 12 (6.9) 
0.9310 
1 375 (44.0) 298 (44.0) 77 (44.0) 
2 261 (30.6) 212 (31.3) 49 (28.0) 
3 142 (16.7) 111 (16.4) 31 (17.7) 
4 24 (2.8) 18 (2.7) 6 (3.4) 
BG-PVS grade, n 
(%) 
0 61 (7.1) 47 (6.9) 14 (7.8) 
0.0422 
1 624 (72.1) 508 (74.2) 116 (64.4) 
2 141 (16.3) 104 (15.2) 37 (20.6) 
3 36 (4.2) 23 (3.4) 13 (7.2) 
4 3 (0.4) 3 (0.4) 0 (0.0) 
MTA grade, n (%) 
0 193 (24.3) 169 (26.6) 24 (15.1) 
<0.00001 
1 375 (47.2) 311 (49.0) 64 (40.3) 
2 162 (20.4) 120 (18.9) 42 (26.4) 
3 50 (6.3) 31 (4.9) 19 (12.0) 
4 14 (1.8) 4 (0.6) 10 (6.3) 
GCA grade, n (%) 
0 285 (33.1) 236 (34.7) 49 (27.2) 
0.106 
1 378 (43.9) 300 (44.1) 78 (43.3) 
2 184 (21.4) 137 (20.1) 47 (26.1) 
3 14 (1.6) 8 (1.2) 6 (3.3) 
     
cSS, presence, n (%) 1 (0.1) 1 (0.2) 0 (0.0) 1.000 
CMB, presence, n (%) 173 (19.8) 133 (19.3) 40 (21.9) 0.441 
Presence of >1 CMB, n (%) 77 (8.8) 55 (8.0) 22 (12.0) 0.087 
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Percentage values were calculated using the total number of patients for whom data was 
available as the denominator. p values are from Mann-Whitney U tests (pvWMH, dWMH, 
CSO-PVS, BG-PVS, MTA and GCA grades), Fisher’s exact test (cSS) or chi-squared tests 
(remainder). BG-PVS, MRI-visible perivascular spaces in the basal ganglia; CMB, cerebral 
microbleed; CSO, MRI-visible perivascular spaces in the centrum semi-ovale; cSS, cortical 
superficial siderosis; dWMH, deep white matter hyperintensities; GCA, global cortical 
atrophy; MTA, medial temporal atrophy; pvWVH, periventricular hyperintensities. 
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Table S3. Multivariable logistic regression for imaging predictors of pre-existing 
cognitive impairment. 
 
 OR 95% CI p value 
Imaging evidence of 
previous cortical infarct, 
presence 
1.27 0.79 to 2.02 0.326 
Lacunes, presence 1.47 0.94 to 2.31 0.093 
    
pvWMH, per grade increase 1.32 1.08 to 1.61 0.006 
dWMH, per grade increase 1.29 1.05 to 1.60 0.016 
    
BG-PVS, per grade increase 1.03 0.77 to 1.36 0.854 
    
MTA, per grade increase 1.55  1.25 to 1.94 <0.0001 
GCA, per grade increase 1.09 0.85 to 1.39 0.503 
    
CMB, presence 0.90 0.57 to 1.40 0.629 
Presence of >1 CMB 1.13 0.63 to 2.05 0.679 
 
Each model considered only a single neuroimaging marker at a time. All remaining models 
were adjusted for age, sex, hypertension, diabetes mellitus, heart failure, known AF, 
educational age, and anti-platelet use. BG-PVS, MRI-visible perivascular spaces in the basal 
ganglia; CI, confidence intervial; CMB, cerebral microbleed; dWMH, deep white matter 
hyperintensities; GCA, global cortical atrophy; MTA, medial temporal atrophy; OR, odds 
ratio; pvWVH, periventricular hyperintensities. 
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Table S4. Logistic regression models reviewing associations between IQCODE-defined 
pre-existing cognitive impairment and functional outcome at 24 months. 
 
 Univariable 
OR (95% CI) 
p value 
Adjusted 
OR (95% CI) 
p value 
Functional dependence  
(mRS > 2) 
2.78 (1.88 to 
4.10) 
<0.0001 
3.33 (1.72 to 
6.42) 
<0.0001 
 
Multivariable model adjusted for age at event, sex, hypertension, hypercholesterolaemia, 
diabetes mellitus, smoking, heart failure, clinical history of previous ischaemic events, 
educational age, admission NIHSS, anti-platelet use, pre-event mRS and the presence of an 
acute DWI lesion at study entry. CI, confidence interval; DWI, diffusion weighted imaging; 
MoCA, Montreal Cognitive Assessment; mRS, modified Rankin scale; NIHSS, National 
Institutes of Health Stroke Scale. 
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